A randomized dose-response trial of citicoline in acute ischemic stroke patients
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non-US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group and the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had a favorable outcome on the Barthel Index at 90 days. There were no drug-related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain
Bazán, N. G. (1970) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(70)90086-x · Cited by 855
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.181486 · Cited by 2,475
Adams, H. P., Adams, R. J., Brott, T., del Zoppo, G. J., Furlan, A., Goldstein, L. B., Grubb, R. L., Higashida, R., Kidwell, C., Kwiatkowski, T. G., et al. (2003) · Stroke · doi:10.1161/01.str.0000064841.47697.22 · Cited by 1,245
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181486 · Cited by 904
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Duncan, P. W., Jorgensen, H. S., & Wade, D. T. (2000) · Stroke · doi:10.1161/01.str.31.6.1429 · Cited by 484
Neuroprotection for ischemic stroke: Two decades of success and failure
Cheng, Y. D., Al-Khoury, L., & Zivin, J. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.36 · Cited by 384
Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
De Keyser, J., Sulter, G., & Luiten, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01463-0 · Cited by 374
White matter injury in ischemic stroke
Wang, Y., Liu, G., Hong, D., Chen, F., Ji, X., & Cao, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.005 · Cited by 309
Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids
Klein, J. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070051 · Cited by 303
Dávalos, A., Alvarez-Sabín, J., Castillo, J., Díez-Tejedor, E., Ferro, J., Martínez-Vila, E., Serena, J., Segura, T., Cruz, V. T., Masjuan, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60813-7 · Cited by 281
Parnetti, L., Amenta, F., & Gallai, V. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00312-8 · Cited by 132
“A neuroprotective activity of carriers of exogenous choline with respect to ischemic damage has already been demonstrated for other choline carriers, both in pre-clinical (Casamenti, 1979; Jope, 1982; Secades, 1995) and clinical studies (Tazaki, 1988; Clark, 1997).”
BackgroundAn Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors?
The Optimising the Analysis of Stroke Trials (OAST) Collaboration (2009) · Stroke · doi:10.1161/strokeaha.108.519207 · Cited by 64
Metadata
- Authors
- Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E., Sabounjian, L. A., & the Citicoline Stroke Study Group
- Venue
- Neurology
- Published
- 1997-09
- Volume
- 49
- Issue
- 3
- Pages
- 671-678
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1974964904
- Cited by
- 221
- References
- 1
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.